恩度联合吉西他滨治疗晚期肝细胞癌临床观察  

Clinical Observation on Endostar Combined with Gemcitabine in the Treatment of Advanced Hepatocellular Carcinoma

作　　者：李绮云[1] 李太东[1] 陈思现[1] 陈永锋[1] 林王美[1] 

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《肿瘤基础与临床》2014年第5期397-399,共3页journal of basic and clinical oncology

摘　　要：目的观察恩度联合吉西他滨治疗晚期肝细胞癌的近期疗效和安全性。方法 57例晚期肝细胞癌患者随机分为2组,治疗组29例给予恩度联合吉西他滨治疗,对照组28例仅给予吉西他滨治疗,2组患者均至少接受2周期的化疗,然后评价近期疗效和毒副反应。结果治疗组有效率为51.7%,高于对照组的25.0%(P<0.05);临床获益率为82.8%,高于对照组的57.1%(P<0.05);中位肿瘤进展时间分别为6.5个月和3.5个月(P<0.05)。2组患者治疗后生活质量评分均有所提高,以治疗组提高更明显(P<0.05)。2组患者治疗后血清AFP、CA19-9水平均有不同程度下降,以治疗组下降较为明显(P<0.05)。2组患者治疗后中、重度毒副反应发生率相近(P>0.05)。结论恩度联合吉西他滨治疗晚期肝细胞癌安全有效,值得临床推广应用。Objective To investigate the short-term effects and safety of endostar combined with gemcitabine in the treatment of advanced hepatocellular carcinoma. Methods Fifty-seven patients with advanced hepatocellular carcinoma were randomly divided into two groups,29 patients of the treatment group received endostar plus gemcit- abine, and 28 patients of the control group received gemcitabine only. All the patients received at least 2 cycles of chemotherapy,and the short-term effects and toxicities were observed. Results The response rate was 51.7% in the treatment group,and was 25.0% in the control group （P 〈0.05）. The clinical benefit rate was 82.8% in the treatment group, and was 57.1% in the control group （P 〈 0.05 ）. The median tumor to progression time was 6.5 months in the treatment group, and was 3.5 months in the control group （P 〈 0.05 ）. The scores of quality of life in the two groups were both increased, and the increasing rate in the treatment group was significantly higher than that in the control group （P 〈 0.05 ）. The serum levels of AFP and CA19-9 in the two groups were decreased significant- ly after the treatment, and the decreasing degree in treatment group was higher than that in the control group （ P 〈 0.05 ）. There were no significant statistical differences in the incidence of moderate-severe toxicities between the two groups. Conclusion Endostar combined with gemcitabine is effeetive and safe in the treatment of advanced hepatocellular carcinoma.

关 键 词：晚期肝细胞癌 恩度 吉西他滨 

分 类 号：R735.7[医药卫生—肿瘤] R730.58[医药卫生—临床医学]